Infection has historically been a major cause of morbidity
Patients and methods and mortality in autologous bone marrow transplantation (ABMT). The daily infusion of hematopoietic growth facSeventy patients undergoing autologous PBPC transplantors, beginning on the day of marrow infusion, significantly tation from June l996 to February l997 were entered into accelerates the rate of neutrophil recovery. [1] [2] [3] The use of this trial. All patients were treated on protocols approved primed peripheral blood progenitor cells (PBPC) further by the Institutional Review Board at the Cleveland Clinic enhances neutrophil recovery and also accelerates platelet Foundation. Patient characteristics are shown in Table 1 . engraftment. [4] [5] [6] [7] Several trials have also demonstrated that Eligibility included adequate cardiac, pulmonary, hepatic the use of G-CSF after autologous PBPC transplantation and renal function prior to transplantation. optimizes neutrophil engraftment. [8] [9] [10] [11] Klumpp et al 9 prospectively randomized 41 patients undergoing autologous
Study schema PBPC transplant (with or without bone marrow) to receive G-CSF (5 g/kg per day) or no growth factors after PBPC The study schema is shown in Figure 1 . Patients were prospectively randomized to begin the initiation of daily G-CSF therapy after autologous PBPC infusion on day 0, day Table  3 . Days to neutrophil engraftment were 10, 11 and 11 days cyclophosphamide 120 mg/kg); or busulfan cyclophosphamide (busulfan 16 mg/kg, cyclophosphamide 120 by treatment group. Platelet engraftment was also similar among the three groups (14, 11 and 14 days, respectively). mg/kg). G-CSF was begun on day 0, day 3 or day +5. When G-CSF was begun on day 0, it was begun 4 h after the A multivariate analysis was performed of variables poten- Table 2 Transplant characteristics
Discussion
Several trials have shown that the use of hematopoietic CSF (300 g/day) beginning on day +1 or day +6. They found no difference in rate of neutrophil or platelet recovery in the two treatment groups. Vey et al 15 have reported Table 3 Median days to engraftment a retrospective series in which patients received G-CSF on either day +1 or day +6 after autologous bone marrow
Group 1 Group 2 Group 3 P
(without PBPC infusion). Granulocyte recovery was similar
in the two treatment groups and more rapid compared to a historical control group which did not receive G-CSF. Our + cell dose with the neutrothis cost saving was a reduction in the utilization of inpatient resources as a result of enhanced engraftment. phil and platelet engraftment, respectively.
Based on our inpatient hospital charges, the cost of a Other strategies have been employed attempting to reduce the cost of autologous progenitor cell transplandaily dose of G-CSF (5 g/kg) for a patient of 70 kg is approximately $200; thus delaying the onset of G-CSF tation. Shifting the care of the patient from a hospital-based setting to that of the outpatient setting may further reduce from day 0 to day +5 results in a cost savings of approximately $1000 per patient. overall charges. 16, 17 However, other costs which may be In summary, we believe that delaying the initiation of 16 
